21
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Distinct proteostasis circuits cooperate in nuclear and cytoplasmic protein quality control

      research-article
      1 , 1 , 1 , 2 , *
      Nature

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Protein misfolding is linked to a wide array of human diseases 1, 2 . Protective cellular protein quality control (PQC) mechanisms evolved to selectively recognize misfolded proteins and limit their toxic effects 3- 9 . Here we examine how molecular chaperones and the ubiquitin (Ub)-proteasome system (UPS) cooperate to recognize and promote the clearance of soluble misfolded proteins. Using a panel of PQC substrates with distinct characteristics and localization, we define distinct chaperone and ubiquitination circuitries executing quality control in the cytoplasm and nucleus. Proteasomal degradation of cytoplasmic misfolded proteins requires tagging with mixed Lysine-48 (K48) and Lysine-11 (K11) linked ubiquitin chains. A distinct combination of E3 ubiquitin ligases and specific chaperones is required to achieve each type of linkage-specific ubiquitination. Strikingly, proteasomal degradation of nuclear misfolded proteins only requires K48 linked Ub chains and is thus independent of K11 specific E3s and chaperones. The distinct Ub codes for nuclear and cytoplasmic PQC appears linked to the function of the ubiquilin Dsk2, which is specifically required for clearance of nuclear misfolded proteins. Together, our work defines the principles of cytoplasmic and nuclear PQC as distinct, involving combinatorial recognition by defined sets of cooperating chaperones and E3s. A better understanding of how these organelle-specific PQC requirements implement proteome integrity has important implications for our understanding of diseases linked to impaired protein clearance and proteostasis disfunction.

          Related collections

          Most cited references47

          • Record: found
          • Abstract: not found
          • Article: not found

          Functional Characterization of the S. cerevisiae Genome by Gene Deletion and Parallel Analysis

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation.

            All seven lysine residues in ubiquitin contribute to the synthesis of polyubiquitin chains on protein substrates. Whereas K48-linked chains are well established as mediators of proteasomal degradation, and K63-linked chains act in nonproteolytic events, the roles of unconventional polyubiquitin chains linked through K6, K11, K27, K29, or K33 are not well understood. Here, we report that the unconventional linkages are abundant in vivo and that all non-K63 linkages may target proteins for degradation. Ubiquitin with K48 as the single lysine cannot support yeast viability, and different linkages have partially redundant functions. By profiling both the entire yeast proteome and ubiquitinated proteins in wild-type and ubiquitin K11R mutant strains using mass spectrometry, we identified K11 linkage-specific substrates, including Ubc6, a ubiquitin-conjugating enzyme involved in endoplasmic reticulum-associated degradation (ERAD). Ubc6 primarily synthesizes K11-linked chains, and K11 linkages function in the ERAD pathway. Thus, unconventional polyubiquitin chains are critical for ubiquitin-proteasome system function.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Adapting proteostasis for disease intervention.

              The protein components of eukaryotic cells face acute and chronic challenges to their integrity. Eukaryotic protein homeostasis, or proteostasis, enables healthy cell and organismal development and aging and protects against disease. Here, we describe the proteostasis network, a set of interacting activities that maintain the health of proteome and the organism. Deficiencies in proteostasis lead to many metabolic, oncological, neurodegenerative, and cardiovascular disorders. Small-molecule or biological proteostasis regulators that manipulate the concentration, conformation, quaternary structure, and/or the location of protein(s) have the potential to ameliorate some of the most challenging diseases of our era.
                Bookmark

                Author and article information

                Journal
                0410462
                6011
                Nature
                Nature
                Nature
                0028-0836
                1476-4687
                11 January 2019
                31 October 2018
                November 2018
                23 August 2019
                : 563
                : 7731
                : 407-411
                Affiliations
                [1 ]Department of Biology and Stanford University, Stanford. California 94305, USA
                [2 ]Genetics, Stanford University, Stanford. California 94305, USA
                Author notes
                Corresponding author: Judith Frydman, Stanford University, Clark Center E200, 318 Campus Drive, Stanford, CA 94305, Tel: 1-650-725-7835, jfrydman@ 123456stanford.edu

                Author contributions

                R.S.S. and J.F. designed the study. C.M.L. performed the initial puncta screens with E3 single and double deletion mutants. R.S.S. performed all other experiments and analysis. R.S.S. and J.F. interpreted the data and wrote the manuscript.

                Author information

                The authors declare no competing financial interests. Correspondence and requests for materials should be addressed to J.F. ( jfrydman@ 123456stanford.edu ).

                [‡]

                Present address: Dimension Therapeutics, Cambridge, Massachusetts 02139, USA

                Article
                NIHMS1006259
                10.1038/s41586-018-0678-x
                6707801
                30429547
                65ea6aac-1b9a-4a50-86c6-d35a835a37e3

                Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Categories
                Article

                Uncategorized
                Uncategorized

                Comments

                Comment on this article